{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:31:40Z","timestamp":1793334700963,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Stoke Therapeutics"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ymthe.2020.12.022","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T04:53:38Z","timestamp":1608872018000},"page":"540-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics"],"prefix":"10.1016","volume":"29","author":[{"given":"Juergen","family":"Scharner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Aznarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.12.022_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2018.08.005","article-title":"Aptamer-based targeted therapy","volume":"134","author":"Zhu","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2020.12.022_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2020.12.022_bib3","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1093\/nar\/gkr089","article-title":"Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes","volume":"39","author":"Koller","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.022_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.022_bib6","first-page":"14","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr","year":"1998","journal-title":"J.\u00a0Int. Assoc. Physicians AIDS Care"},{"key":"10.1016\/j.ymthe.2020.12.022_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40262-014-0224-4","article-title":"Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (Kynamro\u00ae): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B","volume":"54","author":"Geary","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ymthe.2020.12.022_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2020.12.022_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3, Suppl","key":"10.1016\/j.ymthe.2020.12.022_bib10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib11","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.12.022_bib12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","article-title":"An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis","volume":"46","author":"Crooke","year":"2005","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib13","series-title":"Kynamro: full prescribing information","author":"Genzyme","year":"2013"},{"key":"10.1016\/j.ymthe.2020.12.022_bib14","series-title":"Kynamro\u00ae (mipomersen sodium) injection prescribing information","author":"Genzyme","year":"2013"},{"key":"10.1016\/j.ymthe.2020.12.022_bib15","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2020.12.022_bib16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.ymthe.2020.12.022_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.022_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1194\/jlr.R009720","article-title":"Genetic determinants of plasma triglycerides","volume":"52","author":"Johansen","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.022_bib21","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1073\/pnas.83.9.2787","article-title":"Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5","volume":"83","author":"Smith","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.022_bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/hum.2015.070","article-title":"Oligonucleotide therapies: the past and the present","volume":"26","author":"Lundin","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2020.12.022_bib24","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.12.022_bib25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2020.12.022_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.12.022_bib27","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.12.022_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2020.12.022_bib30","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.12.022_bib31","series-title":"FDA approves first drug for spinal muscular dystrophy","year":"2016"},{"key":"10.1016\/j.ymthe.2020.12.022_bib32","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2020.12.022_bib33","first-page":"498","article-title":"The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion","volume":"45","author":"Koenig","year":"1989","journal-title":"Am. J. Hum. Genet."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.022_bib34","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0960-8966(02)00086-X","article-title":"Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy","volume":"12","author":"Aartsma-Rus","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2020.12.022_bib35","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0960-8966(99)00010-3","article-title":"Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides","volume":"9","author":"Wilton","year":"1999","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2020.12.022_bib36","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1089\/hum.2006.061","article-title":"Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle","volume":"18","author":"Arechavala-Gomeza","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/nat.2017.0682","article-title":"Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib39","series-title":"Eteplirsen briefing document NDA 206488","year":"2016"},{"key":"10.1016\/j.ymthe.2020.12.022_bib40","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2020.12.022_bib41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajpath.2011.03.050","article-title":"Restoring dystrophin expression in Duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through","volume":"179","author":"Hoffman","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib43","series-title":"FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation","year":"2019"},{"key":"10.1016\/j.ymthe.2020.12.022_bib44","series-title":"FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation","year":"2020"},{"key":"10.1016\/j.ymthe.2020.12.022_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1056\/NEJMra1705346","article-title":"Treating disease at the RNA level with oligonucleotides","volume":"380","author":"Levin","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.022_bib46","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.022_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)80412-2","article-title":"Innate immunity: the virtues of a nonclonal system of recognition","volume":"91","author":"Medzhitov","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.12.022_bib48","doi-asserted-by":"crossref","first-page":"314ra185","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.12.022_bib49","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib50","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.4049\/jimmunol.167.7.3555","article-title":"Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells","volume":"167","author":"Takeshita","year":"2001","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-0716-0872-2_4","article-title":"CpG oligonucleotides as vaccine adjuvants","volume":"2197","author":"Kayraklioglu","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the CpG adjuvant 1018: a case study","volume":"1494","author":"Campbell","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nri1329","article-title":"Immunotherapeutic uses of CpG oligodeoxynucleotides","volume":"4","author":"Klinman","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib54","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2567.2007.02530.x","article-title":"Impact of class A, B and C CpG-oligodeoxynucleotides on in\u00a0vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals","volume":"120","author":"Martinson","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2020.12.022_bib55","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.166.4.2372","article-title":"Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs","volume":"166","author":"Verthelyi","year":"2001","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib56","first-page":"83","article-title":"Pharmaceutical approval update","volume":"43","author":"Kaufman","year":"2018","journal-title":"P&T"},{"key":"10.1016\/j.ymthe.2020.12.022_bib57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vaccine.2005.08.095","article-title":"Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults","volume":"24","author":"Halperin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2020.12.022_bib58","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.vaccine.2012.01.087","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2020.12.022_bib59","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40\u201370 years of age","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2020.12.022_bib60","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.vaccine.2012.02.001","article-title":"Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine","volume":"30","author":"Sablan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2020.12.022_bib61","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.vaccine.2014.12.060","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus","volume":"33","author":"Janssen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2020.12.022_bib62","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1016\/j.vaccine.2013.05.067","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease","volume":"31","author":"Janssen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2020.12.022_bib63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0167-4781(99)00138-4","article-title":"2\u2032-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation","volume":"1489","author":"Manoharan","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2020.12.022_bib64","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/9304","article-title":"Crystal structure and improved antisense properties of 2\u2032-O-(2-methoxyethyl)-RNA","volume":"6","author":"Teplova","year":"1999","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib65","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/nar\/26.16.3694","article-title":"Structural characteristics of 2\u2032-O-(2-methoxyethyl)-modified nucleic acids from molecular dynamics simulations","volume":"26","author":"Lind","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib66","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1039\/c2cc32286b","article-title":"Structure and nuclease resistance of 2\u2032,4\u2032-constrained 2\u2032-O-methoxyethyl (cMOE) and 2\u2032-O-ethyl (cEt) modified DNAs","volume":"48","author":"Pallan","year":"2012","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.ymthe.2020.12.022_bib67","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib68","doi-asserted-by":"crossref","first-page":"30377","DOI":"10.1038\/srep30377","article-title":"Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides","volume":"6","author":"Kasuya","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.12.022_bib69","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1093\/nar\/gku142","article-title":"Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides","volume":"42","author":"Burdick","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib70","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/bcp.12738","article-title":"Antisense-mediated reduction of proprotein convertase subtilisin\/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial","volume":"80","author":"van Poelgeest","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm801294h","article-title":"Short antisense oligonucleotides with novel 2\u2032-4\u2032 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals","volume":"52","author":"Seth","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ymthe.2020.12.022_bib72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","article-title":"STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial","volume":"6","author":"Reilley","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2020.12.022_bib73","first-page":"562","article-title":"Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides","volume":"2","author":"Geary","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ymthe.2020.12.022_bib74","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1016\/S0021-9258(20)65184-5","article-title":"Effect of deoxynucleoside phosphorothioates incorporated in DNA on cleavage by restriction enzymes","volume":"257","author":"Vosberg","year":"1982","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2020.12.022_bib75","doi-asserted-by":"crossref","first-page":"13456","DOI":"10.1093\/nar\/gku1115","article-title":"Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages","volume":"42","author":"Wan","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib76","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1093\/nar\/23.24.5000","article-title":"Stereodifferentiation\u2014the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H","volume":"23","author":"Koziolkiewicz","year":"1995","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib77","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0968-0896(99)00275-8","article-title":"Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties","volume":"8","author":"Yu","year":"2000","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ymthe.2020.12.022_bib78","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/nar\/gkaa031","article-title":"Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides","volume":"48","author":"\u00d8stergaard","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib79","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1093\/nar\/19.21.5883","article-title":"Novel route to oligo(deoxyribonucleoside phosphorothioates). Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside phosphorothioates)","volume":"19","author":"Stec","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib80","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib81","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/anie.200804408","article-title":"Stereocontrolled solid-phase synthesis of oligonucleoside H-phosphonates by an oxazaphospholidine approach","volume":"48","author":"Iwamoto","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ymthe.2020.12.022_bib82","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1016\/S0960-894X(98)00450-8","article-title":"Solid-phase stereoselective synthesis of 2\u2032-O-methyl-oligoribonucleoside phosphorothioates using nucleoside bicyclic oxazaphospholidines","volume":"8","author":"Guo","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ymthe.2020.12.022_bib83","doi-asserted-by":"crossref","first-page":"16031","DOI":"10.1021\/ja805780u","article-title":"Solid-phase synthesis of stereoregular oligodeoxyribonucleoside phosphorothioates using bicyclic oxazaphospholidine derivatives as monomer units","volume":"130","author":"Oka","year":"2008","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2020.12.022_bib84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-0716-0771-8_4","article-title":"Development of antisense oligonucleotide gapmers for the treatment of Huntington\u2019s disease","volume":"2176","author":"Aslesh","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib85","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/nat.2013.0443","article-title":"Characterization of target mRNA reduction through in\u00a0situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals","volume":"23","author":"Hung","year":"2013","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib86","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1073\/pnas.1613203114","article-title":"Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy","volume":"114","author":"Echigoya","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.022_bib87","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMcibr1613559","article-title":"Targeting therapeutic oligonucleotides","volume":"376","author":"Levin","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.022_bib88","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2020.12.022_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","article-title":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","volume":"237","author":"Sugo","year":"2016","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2020.12.022_bib90","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.12.022_bib91","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.022_bib92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/nat.2013.0448","article-title":"Peptide conjugation of 2\u2032-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice","volume":"24","author":"Jirka","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib93","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1073\/pnas.84.3.648","article-title":"Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site","volume":"84","author":"Lemaitre","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.022_bib94","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-penetrating peptides: from basic research to clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2020.12.022_bib95","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.molmed.2015.06.005","article-title":"Cell-penetrating peptides: strategies for anticancer treatment","volume":"21","author":"Raucher","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymthe.2020.12.022_bib96","first-page":"132","article-title":"Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA","volume":"7","author":"Juliano","year":"2005","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2018.0747","article-title":"Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment","volume":"29","author":"Gait","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib98","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/mt.2008.120","article-title":"Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice","volume":"16","author":"Jearawiriyapaisarn","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib99","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/mt.2011.79","article-title":"Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice","volume":"19","author":"Yin","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gt.2015.8","article-title":"Ameliorating pathogenesis by removing an exon containing a missense mutation: a potential exon-skipping therapy for laminopathies","volume":"22","author":"Scharner","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.022_bib101","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-030-27378-1_15","article-title":"In\u00a0vivo assessment of potential therapeutic approaches for USH2A-associated diseases","volume":"1185","author":"Pendse","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymthe.2020.12.022_bib102","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1038\/s41467-020-17093-9","article-title":"Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression","volume":"11","author":"Lim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.12.022_bib103","doi-asserted-by":"crossref","first-page":"eaaz6100","DOI":"10.1126\/scitranslmed.aaz6100","article-title":"Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome","volume":"12","author":"Han","year":"2020","journal-title":"Sci. Transl. Med."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620306808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620306808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:01:38Z","timestamp":1761501698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620306808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1525001620306808"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.022","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}